form8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934
 
Date of Report (date of earliest event reported): April 22, 2013
 
MIMEDX GROUP, INC.
(Exact name of registrant as specified in charter)
 
Florida
000-52491
26-2792552
 (State or other jurisdiction of incorporation)
 (Commission File Number)
 (IRS Employer Identification No.)
 
60 Chastain Center Blvd., Suite 60
Kennesaw, GA
  
30144
(Zip Code)
(Address of principal executive offices)
    
 
(678) 384-6720
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 8.01
Other Events
 
On April 22, MiMedx Group, Inc., (“MiMedx” or the “Company”) issued a press release announcing that The NASDAQ Capital Market had approved the Company’s application to have its common stock listed for trading under the symbol “MDXG” on The NASDAQ Capital Market, effective as of the beginning of trading on April 25, 2013.  A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
 
Item 9.01
Financial Statements and Exhibits
 
(c) Exhibits
 
Exhibit No.
  
Description
     
 
MiMedx Group, Inc. Press Release, dated April 22, 2013
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
MIMEDX GROUP, INC.
  
       
Dated: April 22, 2013
 By:
/s/: Michael J. Senken
   
Michael J. Senken, Chief Financial Officer
 
 
2